Evaluation of The Serum Level of Osteocalcin in Breast Cancer Patients, and Its Association with Estrogen and Progesterone Receptors

Abstract

Background: Breast cancer is the second leading reason of cancer-related deaths in women. Osteocalcin (OC) is increased when bone metabolism is raised. Cancer cells with estrogen and progesterone receptors be determined by estrogen and related hormones, such as progesterone, to grow. Aim: To find the level of serum osteocalcin, and its association with estrogen receptors and progesterone receptors. Methods: Study design: A cross-sectional study was designed; taking 45 patients with breast cancer and 22 controls women whose ages were between 25-70 years old, from beginning of January 2021 to ending of June 2021. These patients came to Kirkuk Teaching Hospital. Age, weight, length, and body mass index (BMI) were recorded. Biochemical analysis: The serum osteocalcin, progesterone receptors (PRs), and estrogen receptors (ERs) levels were measured by an automated immunoassay system. Results: Mean of BMI of control group was (25.63 ± 1.93) kg/m 2 and of the patients' group was (26.97±4.08) kg/m 2 . There was a significant difference in osteocalcin between the control and patients' group. There was a significant difference in ER between the control and patients' group. There was a significant difference in PR between the control and patients' group. Conclusion: Biochemical marker of bone metabolism may identify patients with bone disease who are at high risk for skeletal-related events.